Cross-Sectional analysis of demographic and clinical characteristics of patients in the United States using icosapent ethyl
Patients taking IPE had characteristics consistent with its indication, including well-controlled LDL-C levels with statin use. The higher triglyceride levels before IPE initiation suggest that IPE may be underutilized in patients at high risk for CV events; however, future studies are needed.
Authors
- Handrean Soran (ORCID: https://orcid.org/0000-0003-1714-5014)
- Hakima Hannachi
- Om P. Ganda (ORCID: https://orcid.org/0000-0002-4779-9273)
- Peter P. Tóth (ORCID: https://orcid.org/0000-0001-5810-5460)
- John Nelson (ORCID: https://orcid.org/0000-0003-2455-0296)
- Nathan D. Wong (ORCID: https://orcid.org/0000-0003-1102-7324)
- Sephy Philip
- Sierra Luciano
- David Abrahamson
- Josh Hartman
Institutions
- Joslin Diabetes Center (US)
- Harvard University (US)
- Johns Hopkins University (US)
- University of California, Irvine (US)
- Manchester University NHS Foundation Trust (GB)
- CGH Medical Center (US)
- Amarin (United States) (US)
- TriNetX (United States) (US)
Publication Details
- Journal
- Frontiers in Cardiovascular Medicine
- Published
- 2025-03-14
- DOI
- https://doi.org/10.3389/fcvm.2025.1411233
- Primary Topic
- Fatty Acid Research and Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- Sanofi
- Alexion Pharmaceuticals
- Regeneron Pharmaceuticals
- Amarin Corporation
- Kowa Company
- Amryt Pharma
- Novo Nordisk
- Amarin Pharma